CRSP · CIK 1674416
What CRISPR Therapeutics AG told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for CRSP. More may follow as additional filings are processed.
In its own words
What could break it.
Other disclosures
- Single-partner (Vertex) dependence for Casgevymedium
CRISPR's only approved product, Casgevy, runs through its collaboration with Vertex — CRISPR receives 40% of the economics (currently insufficient to cover program expenses and bearing 40% of losses) and relies on Vertex even to submit regulatory applications for the hemoglobinopathies program — so its commercial fortunes hinge on a single partner.
“pursuant to our Amended A&R Vertex JDCA, we have relied on Vertex for submitting such applications for our hemoglobinopathies product”
SEC filing →As of 2026
Regulatory & policy
- US drug-pricing reform & pharma import tariffsmedium
CRISPR faces U.S. drug-pricing and trade policy risk: proposed most-favored-nation models (GLOBE for Part B, GUARD for Part D), OBBBA Medicaid funding/enrollment cuts, and a September 2025 announced (currently on-hold) 100% tariff on brand-name/patented drugs unless manufacturing moves to the U.S., which could hurt pricing, demand and its supply chain.
“in September 2025, the current administration also announced a 100% tariff on brand-name or patented drugs unless pharmaceutical companies expand their manufacturing operations in the U.S., and may impose more restrictions on goods. Although the pharmaceutical tariff is currently on hold, this could have a material adverse effect on our supply chain and business prospects as well as the larger biopharmaceutical industry.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Vertex Pharmaceuticals Incorporated
“we accounted for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to CASGEVY allocated 60% to us and 40% to CRISPR, subject to certain adjustments... We also share with CRISPR 40% of the net commercial profits or losses incurred with respect to CASGEVY”
Cited →Vertex Pharmaceuticals Incorporated
“we receive 40% through our collaboration arrangement with Vertex. This amount is currently insufficient to cover program expenses and as such, we are responsible for 40% of losses, subject to certain limitations.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch